InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR – Get Rating) in a research note issued on Wednesday. The brokerage set a “sell” rating on the stock.

Shares of NSPR opened at $1.93 on Wednesday. The stock’s 50-day moving average is $2.30. The firm has a market capitalization of $16.06 million, a PE ratio of -0.92 and a beta of 1.39. InspireMD has a 12 month low of $1.80 and a 12 month high of $6.82.

About InspireMD (Get Rating)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.

See Also

• Get a free copy of the StockNews.com research report on InspireMD (NSPR)
• ABM Industries, A Clean Play For Dirty Economic Times 
• This Still Isn’t A Buyable Bottom For Stocks 
• Should Silver Stocks Be A Part Of Your Portfolio?
• Don’t Get Too Bullish On Lennar Even Though It’s A Good Buy 
• Dividend-Paying Midstream Oil Companies That Could Help You The Mitigate Market Volatility

Want More Great Investing Ideas?